Senior Vice President, and Chief Financial Officer · CytomX Therapeutics, Inc. (CTMX)

Chris Ogden

A named executive officer of CytomX Therapeutics in every fiscal year CompBrief holds from FY2024 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2025

$1,542,631

Salary $478,650Stock awards $224,928

FY2024: $914,279

3rd of 3 named executive officers at CytomX Therapeutics by FY2025 total.

3 named officers on file for CytomX Therapeutics, FY2025

Chris Ogden’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 30, 2026 (DEF 14A).

Free

Get Chris Ogden’s full pay file as a PDF — free

More than this page: up to 10 years of Chris’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Chris Ogden compensation by year

CytomX Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024FY2025
Salary$424,652$478,650
Stock awards$219,275$224,928
Option awards$265,352$446,369
Non-equity incentive—$387,684
Pension and deferred compensation$0$0
All other$5,000$5,000
Total$914,279$1,542,631

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 30, 2026, accession 0001140361-26-018237, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-26-018237. Every figure is read from that document and cited to the page and table it appears in. Filed April 30, 2026.

$914K
$1.5M
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU57,500$244,950—
RSU44,000$187,440—
PSU39,150$166,779—
PSU37,500$159,750—
RSU26,666$113,597—
RSU11,666$49,697—
PSU37,500$38,625—
RSU8,333$35,499—
RSU1,822$7,762—
Option608—$4.13
Option21,875—$2.59
Option80,209—$1.68

Per the Outstanding Equity Awards at Fiscal Year-End table in CytomX Therapeutics, Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 16 award rows shown.

CytomX Therapeutics’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Sean McCarthyChief Executive Officer and Chairman of the Board of Directors$4,738,495
Rachael LesterSenior Vice President and Chief Business Officer$2,234,874
Chris Ogden · this pageSenior Vice President, and Chief Financial Officer$1,542,631

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Chris Ogden's compensation dossier · One-time report. No refunds.